Turner Investments’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Turner Investments’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-109,436	Closed	-$946K	–	297
2016 Q4	$946K	Sell	109,436 -67,770	-38%	-$501K	0.38%	98
2016 Q3	$1.12M	Buy	177,206 +50,080	+39%	+$303K	0.37%	93
2016 Q2	$536K	Sell	127,126 -109,730	-46%	-$530K	0.17%	137
2016 Q1	$1.03M	Sell	236,856 -15,929	-6%	-$70.9K	0.28%	111
2015 Q4	$1.55M	Hold	252,785	–	–	0.32%	92
2015 Q3	$1.45M	Hold	252,785	–	–	0.29%	107
2015 Q2	$1.89M	Sell	252,785 -100,355	-28%	-$607K	0.35%	97
2015 Q1	$2.11M	Buy	353,140 +229,430	+185%	+$1.44M	0.38%	91
2014 Q4	$935K	Sell	123,710 -70,520	-36%	-$422K	0.11%	280
2014 Q3	$1.01M	Buy	+194,230	New	+$968K	0.06%	351

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Turner Investments's PGNX Position: Q1 2017 in Review

Turner Investments sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2017, closing a stake of 109,436 shares — an estimated $946K sold.

Turner Investments first reported a position in PGNX in Q3 2014 and held it in 10 quarters. The position peaked at $2.11M in Q1 2015. 159 funds tracked by Wall St. Rank hold PGNX as of Q1 2017.

Turner Investments reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
Turner Investments sold 109,436 Progenics Pharmaceuticals Inc shares in Q1 2017, an estimated $946K.
Turner Investments first reported a position in Progenics Pharmaceuticals Inc in Q3 2014 and held it in 10 quarters.
Turner Investments's Progenics Pharmaceuticals Inc position peaked at $2.11M in Q1 2015.
159 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2017.

Based on Turner Investments's 13F filing for Q1 2017, filed 11 May 2017.